STOCK TITAN
  1. Home
  2. News
  3. CYTH

Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that N. Scott Fine, Chief Executive Officer, Sharon H. Hrynkow, PhD, Chief Scientific Officer, Senior Vice President for Medical Affairs, and Gerald F. Cox, MD, PhD, Acting Chief Medical Officer of Cyclo Therapeutics will present at the virtual JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 12:30 PM ET.

A live video webcast of the presentation will be accessible on the Company’s website (www.cyclotherapeutics.com) and will be archived for 90 days following the event.

About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.

Stock CYTH logo
Cyclo Therapeutics, Inc.

NASDAQ:CYTH

CYTH Rankings

#4825 Ranked by Market Cap
#4676 Ranked by Stock Gains
N/A Ranked by Dividends

CYTH Latest News

Mar 18, 2024
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Mar 14, 2024
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
Jan 29, 2024
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
Dec 27, 2023
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
Dec 18, 2023
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

CYTH Stock Data

43.36M
15.87M
39.48%
9.76%
0.16%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
GAINESVILLE

About CYTH

cyclodextrin technologies development, inc. (ctd), the "company"​, was organized as a florida corporation on august 9, 1990 with operations beginning july, 1992. in may of 1994 the company became a fully reporting public company listed on the otc bb under the symbol ctdi. in 2000, the company altered its corporate structure to a holding company with subsidiary companies. the otc bb symbol was changed to ctdh. ctd holdings, inc. (the "company"​) was originally formed to market and sell cyclodextrins and related products to the food, pharmaceutical, and other industries; it also provided consulting services related to cyclodextrin technology. ctdh, as a holding company, will acquire, create, and invest in companies that will develop, market, and/or sell products containing cyclodextrins. the company currently operates four wholly owned subsidiaries: ctd, inc.; nanosonic products, inc.; sphingo biotech, inc.; and ferrazo environmental technologies, inc.